- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketMarket MoversStocksIndicesMutual FundsIPOQuarterly Results
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare UTI Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.25 | 1.88 |
NAV | ₹296.60 | ₹40.71 |
Fund Started | 01 Aug 2005 | 25 Jun 2018 |
Fund Size | ₹1098.70 Cr | ₹5727.59 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
4.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.25
1.88
NAV
₹296.60
₹40.71
Fund Started
01 Aug 2005
25 Jun 2018
Fund Size
₹1098.70 Cr
₹5727.59 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 19.54% | 19.49% |
3 Year | 26.66% | 29.01% |
5 Year | 21.88% | 24.12% |
1 Year
19.54%
19.49%
3 Year
26.66%
29.01%
5 Year
21.88%
24.12%
Holding Analysis
Equity | 98.90% | 96.45% |
Cash | 1.09% | 3.55% |
Equity
98.90%
96.45%
Cash
1.09%
3.55%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.08% |
Cipla Ltd. | 5.48% |
Ajanta Pharma Ltd. | 4.92% |
Procter & Gamble Health Ltd. | 4.30% |
Dr. Reddy's Laboratories Ltd. | 4.20% |
Glenmark Pharmaceuticals Ltd. | 3.99% |
Lupin Ltd. | 3.53% |
Apollo Hospitals Enterprise Ltd. | 3.49% |
Divi's Laboratories Ltd. | 3.47% |
Fortis Healthcare Ltd. | 3.36% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.95% |
Dr. Reddy's Laboratories Ltd. | 8.92% |
Cipla Ltd. | 7.75% |
Aurobindo Pharma Ltd. | 6.06% |
Biocon Ltd. | 5.02% |
Mankind Pharma Ltd. | 4.20% |
Alkem Laboratories Ltd. | 4.01% |
Lupin Ltd. | 3.79% |
Gland Pharma Ltd. | 3.57% |
Fund Manager
Name | Kamal Gada | Dharmesh Kakkad |
Start Date | 02 May 2022 | 23 Feb 2021 |
Name
Kamal Gada
Dharmesh Kakkad
Start Date
02 May 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 01 Aug 2005 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
01 Aug 2005
25 Jun 2018